4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide | 617690-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
• 英文别名: SK-7041
• CAS: 617690-98-9
• 化学式: C₁₉H₂₁N₃O₃
• 分子量: 339.394
• InChiKey: WWMASNYTEATYTC-KPKJPENVSA-N

物化性质

• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  81.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(二甲氨基)-N-[(4-甲酰基苯基)甲基]苯甲酰胺 在 羟胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 2.0h， 生成 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors

  摘要：

  Inhibitors of histone deacetylases (HDACs) have been shown to induce differentiation and/or apoptosis of human tumor cells. Novel 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides have been prepared as a new class of HDAC inhibitors and evaluated for their antiproliferative activity and HDAC inhibitory activity. Incorporation of a 1,4-phenylene carboxamide linker, shown by 5, and a 4-(dimethylamino)phenyl or 4-(pyrrolidin-1-yl)phenyl group as a cap substructure generated highly potent hydroxamic acid-based HDAC inhibitors 5a and 5b.

  DOI：

  10.1021/jm030377q

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• [EN] alpha,beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE DOLLAR G(A), DOLLAR G(B)-INSATURES ET LEUR UTILISATION COMME INHIBITEURS DE L'HISTONE DESACETYLASE
  申请人：SK CHEMICALS CO LTD

  公开号：WO2003087066A1

  公开（公告）日：2003-10-23

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  揭示了抑制组蛋白去乙酰化酶的药剂。更具体地，本发明涉及新型羟基胺基酸衍生物或其药用盐，用作抗癌剂或其他治疗剂，基于它们对组蛋白去乙酰化酶的抑制活性。
• Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
  申请人：Kim Dae-Kee

  公开号：US20050124679A1

  公开（公告）日：2005-06-09

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  本发明揭示了一种抑制组蛋白去乙酰化酶的药剂。更具体地说，本发明涉及一种新型的羟酰胺衍生物或其药学上可接受的盐，用作抗癌剂或其他治疗剂，基于它们的组蛋白去乙酰化酶抑制活性。
• Compositions and methods for treating kabuki syndrome and related disorders
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10568854B2

  公开（公告）日：2020-02-25

  A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amount sufficient to produce a physiologically acceptable ketosis in the subject. A method for selecting a subject for treatment of a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) is also provided. Ketogenic compositions and kits useful for practicing the methods are also provided.

  本发明提供了一种方法，用于治疗有需要的受试者的孟德尔表观遗传机制紊乱（如卡布基综合征）。特别是，该方法包括向受试者施用生酮组合物，其用量足以在受试者体内产生生理上可接受的酮病。还提供了一种选择受试者治疗孟德尔表观遗传机制紊乱（如歌舞伎综合征）的方法。还提供了用于实施这些方法的生酮组合物和试剂盒。
• Use of histone deacetylase inhibitors for enhancing immunotherapies
  申请人：Indiana University Research and Technology Corporation

  公开号：US10813919B2

  公开（公告）日：2020-10-27

  Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.

  本研究公开了包括I类组蛋白去乙酰化酶（HDAC）抑制剂和程序性细胞死亡蛋白1（PD-1）抑制剂的组合物，用于增强抗肿瘤活性。还公开了施用这些组合物作为免疫疗法以抑制肾细胞癌中调节性 T 细胞的方法。